Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?

If you hold Pfizer (PFE) or Zoetis (ZTS), you hold the same idea: a branded medicine becomes a standard of care and keeps earning for years, in people or in animals. That is where it stops. Pfizer is buying replacements for older drugs losing exclusivity. Zoetis is cutting its effective price to keep the franchises it has. Same bet, two opposite defenses.

Which Company Just Raised, And Which One Cut?

Pfizer lifted the midpoint of its 2026 revenue guidance by $500 million while cutting its COVID-19 revenue expectation to about $4 billion from about $5 billion. The rest of the company covered that gap: excluding COVID products, the underlying business grew 5% operationally in the second quarter of 2026, with Eliquis and Padcev among the drivers management named.

Zoetis cut its 2026 outlook and now expects revenue to decline 1% to 3% on an organic operational basis. Management said sales trends through July had not yet indicated market stabilization. Pfizer’s raise rests on business it can already see. Zoetis has yet to see visibility on market stabilization.

What Are You Paying For Pfizer’s Answer?

Pfizer is buying growth and cutting cost, and expects about $9.7 billion in total net savings through 2029. What that funds is an aim, not a guide: a risk-adjusted high single-digit revenue CAGR from year-end 2028 through year-end 2033.

The pipeline behind that aim is expensive to get wrong. A Phase III lung cancer trial that missed its primary endpoint and, to a lesser extent, the removal of revenue projections for Oxbryta led to $4.3 billion of noncash intangible asset impairments recorded in the second quarter of 2026. While an unadjusted price-to-EBIT comparison puts Pfizer at 23.9 against Zoetis at 9.2, aligning the two on operating income brings them to 9.7x and 9.0x, largely erasing the paying-up premium.

Is Zoetis The Better Business At The Worse Moment?

Zoetis is fighting rivals for existing patients. New entrants are buying share with discounting, rebates and bundling while clinic visits slide, and Companion Animal revenue fell 6% on an organic operational basis in the second quarter of 2026, with Key Dermatology down 16%. Its answer is gross-to-net investments in Dermatology and U.S. price adjustments on Cerenia and Convenia against generic competition, which management says weighed on price realization.

Livestock revenue grew 11% in the same quarter and Companion Animal Diagnostics grew 12%, on the same basis. Zoetis is still the more profitable of the two, posting an operating margin of 37.6% against Pfizer’s core 26.7% (which narrows to an unadjusted 10.8% EBIT margin after impairment charges). Over three years Zoetis revenue growth has averaged 5.0%, while Pfizer’s has averaged -5.2%.

So on trailing numbers Zoetis wins on valuation, growth, margins and the balance sheet. Pfizer wins the forward signal, and its stock has already had the better run: Pfizer returned 21.1% over the past twelve months while Zoetis lost 50.8%.

On the trailing evidence Zoetis is the better business at the better price, and Pfizer is the better news at the higher multiple. However, chasing recent momentum carries its own valuation and timing risks. A five-factor scorecard ranks every stock on growth, profitability, stability, resilience, and valuation.

So Do You Own The Comeback Or The Discount?

Neither of these settles inside a quarter, and the discount is the better answer only if you can sit through a price war.

Put both side by side in the Pfizer peer comparison on valuation, growth, margins, and returns. Then stop deciding one pair at a time, which is the job the Trefis High Quality Portfolio does. That portfolio has a track record of outpacing the three major indices.